|1.||Syrris, Petros: 7 articles (05/2015 - 08/2005)|
|2.||Saffitz, Jeffrey E: 6 articles (08/2012 - 01/2004)|
|3.||McKenna, William J: 5 articles (08/2012 - 08/2005)|
|4.||Green, Kathleen J: 4 articles (11/2015 - 05/2003)|
|5.||Asimaki, Angeliki: 4 articles (08/2012 - 05/2009)|
|6.||McGrath, John A: 4 articles (12/2007 - 02/2002)|
|7.||Thiene, Gaetano: 4 articles (02/2006 - 11/2002)|
|8.||McLean, W H Irwin: 3 articles (11/2015 - 02/2002)|
|9.||Borradori, Luca: 3 articles (04/2014 - 05/2003)|
|10.||Favre, Bertrand: 3 articles (04/2014 - 05/2003)|
|1.||Pemphigus (Pemphigus Vulgaris)
01/01/2011 - "The identification of a subset of pemphigus foliaceus and pemphigus vulgaris patients that recognizes desmoplakins by this laboratory tool is critical to avoid the misdiagnosis of paraneoplastic pemphigus."
05/01/2007 - "Anti-desmoplakin (DP) I and II are detected in patients with paraneoplastic pemphigus. "
07/01/1989 - "In addition, spinous cells in epidermis are reactive with a mouse monoclonal antibody to desmoplakin, a desmosomal component immunologically distinct from pemphigus. "
03/01/1986 - "By double indirect immunofluorescence the desmoplakin antiserum stains a double fluorescent line along the contacting edges of cultured keratinocytes, whereas the positive pemphigus serum samples stain a single fluorescent line along this same border. "
03/01/1986 - "Tissue sections of mouse skin processed for double indirect immunofluorescence using each of the pemphigus serum samples and a rabbit antiserum directed against a component of the desmosomal plaque (desmoplakin) show similar punctate cell surface staining patterns. "
11/01/1988 - "Our study demonstrates that most infiltrating breast carcinomas retain abundant desmoplakin, regardless of tumor grade, degree of differentiation, or tumor type (duct or lobular). "
11/01/1988 - "Using a monoclonal antibody specific for desmoplakin, we evaluated 52 breast carcinomas, 25 normal tissues, 10 benign breast lesions, and 14 nonepithelial tumors. "
01/01/2015 - "Importantly, siRNA conferred depletion of CSPP-L or Desmoplakin promoted multi-lumen spheroid formation in 3D-cultures of non-ciliated human colon carcinoma Caco-2 cells. "
06/01/1999 - "Two constitutive desmosomal molecules, desmoplakin (Dp) and plakoglobin (Pg), were examined in 26 samples of primary carcinoma of the head and neck. "
03/01/1995 - "Changes in expression of neural cell-adhesion molecule ard desmoplakin associated with phenotypic transitions in cloned cell-lines from a nonsmall cell lung-carcinoma."
01/01/1998 - "Immunoprecipitation of lysates from radiolabeled human keratinocytes with the patient's serum revealed circulating antibodies against 210-kD (desmoplakin II), 190- and 170-kD antigens but none against the 230-kD antigen or 250-kD desmoplakin I. Under cytostatic chemotherapy the lymphomas showed complete and long-lasting remission, whereas the mucocutaneous lesions persisted. "
08/01/1995 - "We used a battery of antibodies directed against the following: cytokeratins (CKs) 5, 10, 17, and 19, actin, cell-adhesion proteins (desmoplakins, desmogleins), markers of terminal epidermal differentiation (filaggrin, involucrin and loricrin), markers of proliferation (PCNA, MIB, K6,16), a marker of endocytosis (clathrin) and markers of cell growth, (transforming growth factor [TGF-alpha]) and B-cell leukemia/lymphoma-2 [bcl-2]. "
04/01/2012 - "Increased desmoplakin I levels, determined within 1-3 months of the first ischemic stroke, could be a biomarker for statin responsiveness against a new vascular event in post-ischemic stroke patients taking statins early (1-3 months) after the ischemic stroke."
04/01/2012 - "Only patients who had been taking statins for 3 months after the ischemic stroke and did not suffer vascular recurrence over a follow-up year, have higher levels of desmoplakin I at the time of inclusion (Odds ratio 0.49; 95% CI: 0.28-0.86; p = 0.013). "
04/01/2012 - "Plasma desmoplakin I biomarker of vascular recurrence after ischemic stroke."
04/01/2012 - "Among the identified proteins, only plasma levels of desmoplakin I were associated with protection against a new vascular event (Odds ratio: 0.64; 95% CI: 0.46-0.89; p = 0.009) after adjustment for hypercholesterolemia, statins and previous atherothrombotic stroke subtype. "
|2.||Proteins (Proteins, Gene)
|9.||Adenosine Triphosphatases (ATPase)
|10.||gamma Catenin (Plakoglobin)
|1.||Drug Therapy (Chemotherapy)